The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-13. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
=== Addiction remission === The term fen-phen was created in 1994 when Pietr Hitzig and Richard B. Rothman reported that this combination could presumptively remit alcohol and cocaine craving. The authors suggested that other combined dopamine and serotonin agonists or precursors might share this therapeutic potential. Subsequent experiments in rats supported these preliminary reports. In 2006 it was confirmed that the combination of phentermine and the serotonin precursor 5-hydroxytryptophan (5-HTP), in place of fenfluramine, significantly decreased alcohol withdrawal seizures in rats. Intramural National Institutes of Health (NIH) double-blind protocols to demonstrate the efficacy of fen-phen in alcohol and cocaine addiction were designed, but never performed.
=== Adventitious routes === It is a by-product in the production of vinylidene chloride. For instance, it can be formed from trichloroethylene. It is also possible to produce dichloroacetylene from trichloroethylene at low concentrations by running the trichloroethylene through nitrogen at 120 °C in the presence of dry potassium hydroxide.
==== Androgenic ==== Androgen replacement therapy for men with low levels of testosterone, such as those associated with late-onset hypogonadism; also effective in improving libido for elderly males. Induction of male puberty: Androgens are given to many boys distressed about extreme delay of puberty. Testosterone is now nearly the only androgen used for this purpose and has been shown to increase height, weight, and fat-free mass in boys with delayed puberty. Masculinizing hormone therapy for transgender men, other transmasculine people, and intersex people, by producing masculine secondary sexual characteristics such as a deeper voice, increased bone and muscle mass, masculine fat distribution, facial and body hair, and clitoral enlargement, as well as mental changes such as alleviation of gender dysphoria and increased sex drive.
Sources: en.wikipedia.org
=== 1960s === During the 1960s, the main conflict in Colombia was between leftist guerillas and the central government. Key concerns included access to land, the battle between communist and far-right ideologies, and the marginalization of peasant populations. In the early 1960s, Colombian Army units loyal to the National Front began to attack peasant communities. This happened throughout Colombia, with the Colombian army deeming these peasant communities as enclaves for bandits and communists. It was the 1964 attack on the community of Marquetalia that motivated the later creation of FARC. Despite the infantry and police encirclement of the villages inside Marquetalia (3,500 men swept through the area), Manuel Marulanda managed to escape the army cordon. Unlike the rural FARC, which had roots in previous Liberal peasant struggles, the National Liberation Army (ELN) was mostly an outgrowth of university unrest. It would subsequently tend to follow a small group of charismatic leaders, including Camilo Torres Restrepo. Both guerrilla groups remained mostly operational in remote areas of the country during the rest of the 1960s. The Colombian government organized several short-lived counter-guerrilla campaigns in the late 1950s and early 1960s. The U.S. government and the CIA aided these efforts, which employed hunter-killer teams and involved U.S. personnel from the previous Philippine campaign against the Huks, who would later participate in the subsequent Phoenix Program in the Vietnam War.
Instead, the company offered to provide the medication free through its patient access program for hardship cases, though this option was described as much more restrictive. Oncologists criticized the decision as unprecedented, with Dr. Carmen de Ramon Ortiz of Geneva University Hospital noting that about 20% of follicular lymphoma patients require intensive treatment and that Lunsumio represents "a very innovative immunotherapy that stimulates the immune system, leading to high remission rates." Industry experts characterized the withdrawal as a form of healthcare rationing and a "canary in the coal mine," noting that only half of EU-approved medications are available in Switzerland. Some experts suggested the withdrawal reflected broader pressures from potential U.S. pricing reforms and trade uncertainties that could affect Roche's largest market, including potential tariff increases on pharmaceutical exports from 10% to up to 31%. The case was viewed by analysts as a potential precedent-setting "regulatory showdown" that could influence pharmaceutical pricing negotiations across the industry, particularly for rare disease treatments affecting small patient populations.
== Phytochemicals == Many plants produce chemical compounds for defence against herbivores. The major classes of pharmacologically active phytochemicals are described below, with examples of medicinal plants that contain them. Human settlements are often surrounded by weeds containing phytochemicals, such as nettle, dandelion and chickweed. Many phytochemicals, including curcumin, epigallocatechin gallate, genistein, and resveratrol are pan-assay interference compounds and are not useful in drug discovery.
Sources: en.wikipedia.org
== Therapeutic effects == Serotonin, given orally at a dose of 100 mg, produced effects in humans including blood pressure changes, abdominal cramps, muscle aches, and a feeling of sedation. In contrast to psychedelic drugs like LSD, no hallucinogenic effects were reported. In other studies, serotonin, at low intravenous doses of 2 to 6 mg, had no effects on electroencephalogram (EEG) readings in humans. In accordance with the preceding findings, it has been stated that administration of serotonin in humans produces no psychoactive effects that cannot be attributed to anxiety by its profound peripheral adverse effects including circulatory disturbance, other autonomic effects, and vomiting. Intracerebroventricular injection of serotonin has been studied in patients with severe psychiatric conditions, but little information about its psychoactive effects is provided. It is thought that exogenous serotonin is too hydrophilic to cross the blood–brain barrier and has too poor of metabolic stability due to rapid metabolism by monoamine oxidase (MAO) such that it cannot produce drug-like central effects in humans with peripheral administration. However, close analogues of serotonin that are more lipophilic and metabolically stable, like bufotenin (N,N-dimethylserotonin), 5-MeO-DMT (N,N,O-trimethylserotonin), and 5-MeO-AMT (α,O-dimethylserotonin), among many others, are active and produce pronounced centrally mediated effects in humans.
=== 2020s === The biomedical response to the COVID-19 pandemic highlighted the rapid translation of advanced platform technologies into clinical practice. The development and deployment of mRNA-based vaccines against SARS-CoV-2 demonstrated the efficacy of nucleic acid therapeutics at a global scale. The 2020s also marked major integration of artificial intelligence into biomedical sciences, exemplified by deep-learning models such as AlphaFold for high-accuracy protein structure prediction, accelerating drug discovery and biological analysis.
The group found that while food did not alter the expression of dynorphin B, it increases dynorphin A levels in several rat brain regions (hypothalamus, nucleus accumbens, and bed nucleus of the stria terminalis). Recent research on dynorphin knockout mice did not find differences between knockout and control animals in food intake, but found that fat storage was reduced in male knockout mice. Fatty acids were oxidized more quickly in knockout animals. Studies have also shown that ingesting a high-fat diet increases the gene expression of dynorphin in the hypothalamus. Thus, dynorphin may cause overeating when a high-fat diet is available. Morley & Levine were the first to describe the role of opioid peptides in stress-related eating. In their study, mice had their tails pinched (causes stress), which induced eating. Stress-related eating was reduced by injecting naloxone, an opioid peptide antagonist. Mandenoff et al. proposed that, although endogenous opioids are not necessary to maintain body weight and energy expenditure under predictable circumstances, they become activated under stressful conditions. They found that endogenous opioids, such as dynorphin, stimulate appetite and decrease energy expenditure. Taken together, the studies above suggest an important evolutionary mechanism in which more food is eaten, more nutrients are stored, and less energy is expended by an organism during times of stress.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.